Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Natco Pharma (Canada) Inc. is a Canadian subsidiary of Natco Pharma Limited, India. Natco Pharma Limited is a vertically integrated pharmaceutical company heavily focused in R&D and in manufacturing drug intermediates, API and finished formulations. It has a global network and customer centric approach.
The company exports API’s and Formulations to around 50 countries across the globe. Well known for its impressive portfolio of Oncology, Neurology and CNS drugs, it is bringing to market niche pharmaceuticals.
Natco Pharma has been supplying high quality pharmaceuticals to the Canadian market for more than five years, and, since its formation, has set up a very professional Quality, Regulatory, Warehousing, Marketing, Distribution and Logistics capability to service the Canadian market.
The company is slated to launch some of its already approved generic products and in the process of getting approvals for some very niche and very significant pipeline of pharmaceuticals.
Contact:
Address: 2550 Argentina Road, Suite 116, Mississauga, ON, L5N 5R1 Canada
Tel.: +1 (905) 997 3353
Website: http://natcopharma.ca/
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Jan Hux is the President and CEO of Diabetes Canada. Canadians have been at the forefront of tackling diabetes since the discovery of insulin. Now that the disease has become…
Brian Hilberdink, President of Novo Nordisk Canada, calls for collaboration between government and industry to ensure that Canadian patients get swift access to the best treatments. As a Canadian who…
John Fowler founded 7ACRES, a licensed producer of cannabis, in 2013. In 2014, 7ACRES went over to become part of The Supreme Cannabis Company, which today stands as a unique…
Mark Ware, the Chief Medical Officer of Canopy Growth Corporation, has intensely investigated the effects of cannabinoids, making him perfectly placed to cover this new era of cannabis in healthcare. …
Canadian medical cannabis company Tilray’s stock surged by over 77 percent in the first three trading days of last week before dropping dramatically by 47.9 percent to close out the…
Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMMS) for PharmaBoardroom. Today more Canadians are dying in this crisis than at the height of…
As cannabis in Canada cruises towards legalization, Pharma giants race for patented products. Big Pharma is establishing a significant cannabis presence in Canada with registered patents in advance of…
While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma –…
Valeant Pharmaceuticals has taken the decision to rename itself in an effort to distance the company from a series of pricing scandals that occurred under previous CEO J. Michael Pearson.…
“If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career…
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
See our Cookie Privacy Policy Here
